Cargando…

Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen

Sex steroids play a key role in bone turnover and preserving BMD; hence, gender‐affirming hormone treatment (HT) in transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they do not provide insights into changes in bone metabolism caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Vlot, Mariska C, Wiepjes, Chantal M, de Jongh, Renate T, T’Sjoen, Guy, Heijboer, Annemieke C, den Heijer, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852079/
https://www.ncbi.nlm.nih.gov/pubmed/31099910
http://dx.doi.org/10.1002/jbmr.3762
_version_ 1783469749318975488
author Vlot, Mariska C
Wiepjes, Chantal M
de Jongh, Renate T
T’Sjoen, Guy
Heijboer, Annemieke C
den Heijer, Martin
author_facet Vlot, Mariska C
Wiepjes, Chantal M
de Jongh, Renate T
T’Sjoen, Guy
Heijboer, Annemieke C
den Heijer, Martin
author_sort Vlot, Mariska C
collection PubMed
description Sex steroids play a key role in bone turnover and preserving BMD; hence, gender‐affirming hormone treatment (HT) in transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they do not provide insights into changes in bone metabolism caused by HT. This study investigated changes in bone turnover markers (BTMs) and sclerostin, as well as their correlations with change in BMD in transwomen and transmen during the first year of HT. Transwomen received estradiol and antiandrogens; transmen received testosterone. Sclerostin; P1NP; alkaline phosphatase (ALP); CTx; and BMD of the total hip, the femoral neck, and the lumbar spine were evaluated at baseline and after 1 year of HT. There were 121 transwomen (median age 30 years, interquartile range [IQR] 24 to 41 years) and 132 transmen (median age 24 years, IQR 21 to 33 years) included in the study. In transwomen, ALP decreased in 19% (95% CI, –21 to–16), CTx in 11% (95% CI, –18 to–4), and sclerostin in 8% (95%CI, –13 to–4) of study participants after 1 year of HT. In contrast, in transmen P1NP, ALP, and sclerostin increased in 33% (95% CI, 24 to 42), 16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20) of study participants, respectively, after 1 year of HT. No age differences were seen in transwomen, whereas in transmen aged ≥50 years a decrease in all BTMs was found in contrast with the other age groups. These transmen had low estrogen concentration at the start of HT based on their postmenopausal state before the start of HT; their estradiol concentrations increased during testosterone treatment. Changes in BTMs and BMD were weakly correlated (correlation coefficient all <0.30). To conclude, 1 year of HT resulted in decreased bone turnover in transwomen and older transmen, whereas it increased in younger transmen. The decrease in bone resorption in older transmen shows the importance of estrogen as a key regulator of bone turnover. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc.
format Online
Article
Text
id pubmed-6852079
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68520792019-11-18 Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen Vlot, Mariska C Wiepjes, Chantal M de Jongh, Renate T T’Sjoen, Guy Heijboer, Annemieke C den Heijer, Martin J Bone Miner Res Original Articles Sex steroids play a key role in bone turnover and preserving BMD; hence, gender‐affirming hormone treatment (HT) in transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they do not provide insights into changes in bone metabolism caused by HT. This study investigated changes in bone turnover markers (BTMs) and sclerostin, as well as their correlations with change in BMD in transwomen and transmen during the first year of HT. Transwomen received estradiol and antiandrogens; transmen received testosterone. Sclerostin; P1NP; alkaline phosphatase (ALP); CTx; and BMD of the total hip, the femoral neck, and the lumbar spine were evaluated at baseline and after 1 year of HT. There were 121 transwomen (median age 30 years, interquartile range [IQR] 24 to 41 years) and 132 transmen (median age 24 years, IQR 21 to 33 years) included in the study. In transwomen, ALP decreased in 19% (95% CI, –21 to–16), CTx in 11% (95% CI, –18 to–4), and sclerostin in 8% (95%CI, –13 to–4) of study participants after 1 year of HT. In contrast, in transmen P1NP, ALP, and sclerostin increased in 33% (95% CI, 24 to 42), 16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20) of study participants, respectively, after 1 year of HT. No age differences were seen in transwomen, whereas in transmen aged ≥50 years a decrease in all BTMs was found in contrast with the other age groups. These transmen had low estrogen concentration at the start of HT based on their postmenopausal state before the start of HT; their estradiol concentrations increased during testosterone treatment. Changes in BTMs and BMD were weakly correlated (correlation coefficient all <0.30). To conclude, 1 year of HT resulted in decreased bone turnover in transwomen and older transmen, whereas it increased in younger transmen. The decrease in bone resorption in older transmen shows the importance of estrogen as a key regulator of bone turnover. © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. John Wiley and Sons Inc. 2019-08-19 2019-10 /pmc/articles/PMC6852079/ /pubmed/31099910 http://dx.doi.org/10.1002/jbmr.3762 Text en © 2019 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Vlot, Mariska C
Wiepjes, Chantal M
de Jongh, Renate T
T’Sjoen, Guy
Heijboer, Annemieke C
den Heijer, Martin
Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title_full Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title_fullStr Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title_full_unstemmed Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title_short Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
title_sort gender‐affirming hormone treatment decreases bone turnover in transwomen and older transmen
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852079/
https://www.ncbi.nlm.nih.gov/pubmed/31099910
http://dx.doi.org/10.1002/jbmr.3762
work_keys_str_mv AT vlotmariskac genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen
AT wiepjeschantalm genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen
AT dejonghrenatet genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen
AT tsjoenguy genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen
AT heijboerannemiekec genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen
AT denheijermartin genderaffirminghormonetreatmentdecreasesboneturnoverintranswomenandoldertransmen